A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms

详细信息    查看全文

• 作者：Brooks D. Cash ; Michael S. Epstein ; Syed M. Shah
• 关键词：Irritable bowel syndrome ; Peppermint oil ; Abdominal pain ; Bloating ; Diarrhea ; l ; menthol
• 刊名：Digestive Diseases and Sciences
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：61
• 期：2
• 页码：560-571
• 全文大小：1,145 KB
• 参考文献：1.Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–1915.PubMed
  2.Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.CrossRef PubMed
  3.Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80.PubMedCentral PubMed
  4.Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2:653–654.PubMedCentral CrossRef PubMed
  5.Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.CrossRef PubMed
  6.Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39:530–536.CrossRef PubMed
  7.European Medicines Agency. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. September 25, 2014. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Scientific_​guideline/​2014/​09/​WC500173457.​pdf . Accessed May 4, 2015.
  8.Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43:541–550.PubMedCentral CrossRef PubMed
  9.Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. 2011;106:1749–1759.CrossRef PubMed
  10.Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40:1023–1034.CrossRef PubMed
  11.Thompson WG. Understanding the irritable gut: The functional gastrointestinal disorders. McLean, VA: Degnon and Associates; 2008:56–59.
  12.Martinez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62:1160–1168.CrossRef PubMed
  13.Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46:421–431.CrossRef PubMed
  14.Martinez C, Vicario M, Ramos L, et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol. 2012;107:736–746.CrossRef PubMed
  15.Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987;92:1885–1893.PubMed
  16.Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol. 2006;101:1288–1294.CrossRef PubMed
  17. Giamarellos-Bourboulis E, Tang J, Pyleris E, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50:1076–1087.
  18.Salvioli B, Serra J, Azpiroz F, et al. Origin of gas retention and symptoms in patients with bloating. Gastroenterology. 2005;128:574–579.CrossRef PubMed
  19.Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988;2:101–118.CrossRef PubMed
  20.Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharmacol Ther. 2003;17:445–451.CrossRef PubMed
  21.Harries N, James KC, Pugh WK. Antifoaming and carminative actions of volatile oils. J Clin Pharm Ther. 1977;2:171–177.CrossRef
  22.Galeotti N, Di Cesare ML, Mazzanti G, Bartolini A, Ghelardini C. Menthol: a natural analgesic compound. Neurosci Lett. 2002;322:145–148.CrossRef PubMed
  23.Hawrelak JA, Cattley T, Myers SP. Essential oils in the treatment of intestinal dysbiosis: a preliminary in vitro study. Altern Med Rev. 2009;14:380–384.PubMed
  24.Juergens UR, Stober M, Vetter H. The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases. Eur J Med Res. 1998;3:539–545.PubMed
  25.Walstab J, Wohlfarth C, Hovius R, et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroenterol Motil. 2014;26:810–820.CrossRef PubMed
  26.Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2010;22:1402–1411.PubMed
  27.Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–S26.CrossRef PubMed
  28.National Collaborating Center for Nursing and Supportive Care (UK). Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. 2008. http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK51953/​ . Accessed May 4, 2015.
  29.Lech Y, Olesen KM, Hey H, Rask-Pedersen E, Ostergaard O, Vilien M. Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo. Ugeskr Laeger. 1988;150:2388–2389.PubMed
  30.Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. 2010;55:1385–1390.CrossRef PubMed
  31.Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997;32:765–768.CrossRef PubMed
  32.Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J. 1979;2:835–836.PubMedCentral CrossRef PubMed
  33.Gelal A, Jacob P III, Yu L, Benowitz NL. Disposition kinetics and effects of menthol. Clin Pharmacol Ther. 1999;66:128–135.CrossRef PubMed
  34.Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol. 1999;94:1320–1326.CrossRef PubMed
  35.Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–512.PubMed
  36.Somerville KW, Richmond CR, Bell GD. Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: a pharmacokinetic study. Br J Clin Pharmacol. 1984;18:638–640.PubMedCentral CrossRef PubMed
  37.European Medicines Agency. Guideline on quality of oral modified release products. March 20, 2014. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Scientific_​guideline/​2014/​07/​WC500170465.​pdf . Accessed May 4, 2015.
  38.U.S.Department of Health and Human Services Food and Drug Administration. Guidance for industry irritable bowel syndrome– Clinical evaluation of drugs for treatment. 2012. http://​www.​fda.​gov/​downloads/​Drugs/​Guidances/​UCM205269.​pdf . Accessed March 29, 2015.
  
• 作者单位：Brooks D. Cash (1)
  Michael S. Epstein (2)
  Syed M. Shah (3)
  
  1. Division of Gastroenterology, University of South Alabama, 6000 University Commons, 75 University Blvd, S, Mobile, AL, 36688, USA
  2. Digestive Disorders Associates, 621 Ridgely Ave, #201, Annapolis, MD, 21401, USA
  3. IM HealthScience LLC, 101 Plaza Real South, Ste 205-S, Boca Raton, FL, 33432, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gastroenterology
  Hepatology
  Oncology
  Transplant Surgery
  Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-2568

文摘

Background Peppermint oil (PO) has shown promise as an IBS therapy, but previous trials have demonstrated variable efficacy and tolerability results.